Shield Therapeutics (STX) Price & Analysis

Compare

28 Followers

STX Stock Chart & Stats

Day’s Range― - ―

52-Week Range2.10p - 9.40p

Previous CloseN/A

Volume699.61K

Average Volume (3M)4.70M

Market Cap

£86.54M

Enterprise Value44.14M

Total Cash (Recent Filing)£10.81M

Total Debt (Recent Filing)£27.05M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,061,802,900

10 Day Avg. Volume3,070,856

30 Day Avg. Volume4,697,525

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-23.24

Price to Sales (P/S)0.97

P/FCF Ratio-3.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£10.50

Price Target Upside31.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Cash Flow$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.

Prescription CoverageThe percentage of non-covered prescriptions dropped from 37% to 22%, contributing to the revenue growth.

Revenue GrowthThe significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.

Bears Say

Cash Flow TimingThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.

Script GrowthNegative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.

Shield Therapeutics News

Shield Therapeutics Announces Share Capital and Market Position of ACCRUFeR®

Shield Therapeutics ( ($GB:STX) ) just unveiled an announcement. Shield Therapeutics has announced that its total issued share...

12d ago

Shield Therapeutics Reports Positive Pediatric Trial Results for Ferric Maltol

Shield Therapeutics ( ($GB:STX) ) has shared an announcement. Shield Therapeutics announced positive results from its Phase 3...

12d ago

Shield Therapeutics Raises £1.5 Million to Boost ACCRUFeR® Growth

Shield Therapeutics ( ($GB:STX) ) just unveiled an update. Shield Therapeutics has successfully raised £1.5 million through a...

28d ago

Shield Therapeutics’ ACCRUFeR® Receives FDA Priority Review for Pediatric Use

An announcement from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics has announced that the FDA...

1M ago

Shield Therapeutics Reports Strong H1 2025 Results and Global Expansion

Shield Therapeutics ( ($GB:STX) ) just unveiled an announcement. Shield Therapeutics reported a significant increase in revenues and...

1M ago

Shield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure Patients

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced positive results from the ORION-HF study,...

2M ago

Shield Therapeutics Reports Strong H1 2025 Results and Global Expansion

The latest update is out from Shield Therapeutics ( ($GB:STX) ). Shield Therapeutics reported a significant increase in...

2M ago

Shield Therapeutics Doubles ACCRUFeR® Revenues in Q2 2025

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported a significant increase in...

3M ago

Shield Therapeutics Secures Shareholder Support at 2025 AGM

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced the successful passing of all resolutions...

5M ago

Shield Therapeutics Reports Strong 2024 Financial Growth and Global Expansion of ACCRUFeR®

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported significant financial growth in...

6M ago

STX FAQ

What was Shield Therapeutics PLC’s price range in the past 12 months?

Shield Therapeutics PLC lowest share price was 2.10p and its highest was 9.40p in the past 12 months.

What is Shield Therapeutics PLC’s market cap?

Shield Therapeutics PLC’s market cap is £86.54M.

When is Shield Therapeutics PLC’s upcoming earnings report date?

Shield Therapeutics PLC’s upcoming earnings report date is Apr 23, 2026 which is in 192 days.

How were Shield Therapeutics PLC’s earnings last quarter?

Shield Therapeutics PLC released its earnings results on Aug 21, 2025. The company reported -0.007p earnings per share for the quarter, missing the consensus estimate of N/A by -0.007p.

Is Shield Therapeutics PLC overvalued?

According to Wall Street analysts Shield Therapeutics PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shield Therapeutics PLC pay dividends?

Shield Therapeutics PLC does not currently pay dividends.

What is Shield Therapeutics PLC’s EPS estimate?

Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shield Therapeutics PLC have?

Shield Therapeutics PLC has 1,061,802,900 shares outstanding.

What happened to Shield Therapeutics PLC’s price movement after its last earnings report?

Shield Therapeutics PLC reported an EPS of -0.007p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.716%.

Which hedge fund is a major shareholder of Shield Therapeutics PLC?

Currently, no hedge funds are holding shares in GB:STX

Shield Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-396.71%

Trailing 12-Months

Asset Growth

22.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shield Therapeutics PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics (STX) Earnings & Revenues

Historic Earnings Reports

STX Stock 12 Month Forecast

Average Price Target

10.50p

▲(31.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"0p","14":"14p","28":"28p","42":"42p","56":"56p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">15.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">10.50p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">6.50p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,14,28,42,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Feb<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.261538461538462,8.823076923076924,9.384615384615385,9.946153846153846,10.507692307692308,11.069230769230769,11.630769230769232,12.192307692307693,12.753846153846155,13.315384615384616,13.876923076923077,14.438461538461539,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.915384615384616,8.13076923076923,8.346153846153847,8.561538461538461,8.776923076923078,8.992307692307692,9.207692307692309,9.423076923076923,9.638461538461538,9.853846153846154,10.069230769230769,10.284615384615385,{"y":10.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.607692307692308,7.515384615384615,7.423076923076923,7.3307692307692305,7.2384615384615385,7.1461538461538465,7.053846153846154,6.961538461538462,6.86923076923077,6.776923076923077,6.684615384615385,6.592307692307692,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.37,"date":1622505600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >